What are Kathleen M. Behrens’ direct share holdings in Sarepta (SRPT) after this Form 4?

After the RSU grant, the Form 4 shows she directly holds 214,357 shares of Sarepta common stock. This figure reflects her direct ownership position reported in the filing and excludes the separate indirect holding reported as being held by a trust.

Sarepta (SRPT) director receives 16,875 RSUs in stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BEHRENS M KATHLEEN reported acquisition or exercise transactions in this Form 4 filing.

Sarepta Therapeutics director Kathleen M. Behrens reported a compensation-related equity grant rather than an open-market trade. She was awarded 16,875 restricted stock units (RSUs), each representing the right to receive one share of common stock at no cost. According to the terms, these RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this grant, she holds 214,357 shares of common stock directly, and a separate filing entry shows 10,000 shares of common stock held indirectly by a trust as a reported holding.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BEHRENS M KATHLEEN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,875	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 214,357 shares (Direct, null); Common Stock — 10,000 shares (Indirect, By Trust)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 16,875 units Grant price per RSU: $0.0000 per unit Direct shares after grant: 214,357 shares +2 more

5 metrics

RSUs granted 16,875 units Restricted stock units awarded to director on 2026-06-04

Grant price per RSU $0.0000 per unit Stated price for compensation grant

Direct shares after grant 214,357 shares Common stock directly held following RSU award

Indirect trust holding 10,000 shares Common stock held indirectly by trust as of 2026-06-04

RSU vesting condition Earlier of 1-year anniversary or next qualifying annual meeting Vesting schedule for RSU award F1

Key Terms

restricted stock units ("RSUs"), vest, annual meeting of stockholders, By Trust

4 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the next annual meeting of stockholders which is at least 50 weeks after..."

By Trust financial

"direct_or_indirect: "I", nature_of_ownership: "By Trust""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 08:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEHRENS M KATHLEEN

(Last)

(First)

(Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		A		16,875	A	⁽¹⁾	214,357	D
Common Stock								10,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for M. Kathleen Behrens	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) report for Kathleen M. Behrens?

Sarepta reported that director Kathleen M. Behrens received a grant of 16,875 restricted stock units. These RSUs are a stock-based compensation award, not an open-market purchase or sale, and each unit represents the right to receive one share of common stock.

How many RSUs did the Sarepta (SRPT) director receive and at what price?

The director received 16,875 restricted stock units at a stated price of $0.0000 per unit. This reflects a compensation grant, where shares are awarded rather than bought in the market, subject to vesting conditions described in the filing footnote.

When will the newly granted Sarepta (SRPT) RSUs vest for the director?

The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. Vesting timing links the award to the company’s regular governance calendar.

Does the Sarepta (SRPT) Form 4 show any indirect holdings for the director?

Yes. One entry reports 10,000 shares of common stock held indirectly "By Trust." This is labeled as a holding entry, indicating shares associated with a trust rather than a new market transaction on the reported date.